The overall mission of the HIV Vaccine Trials Network is to fully characterize the safety, immunogenicity, and efficacy of HIV vaccine candidates with the goal of developing a safe, effective vaccine as rapidly as possible for prevention of HIV infections globally. The Duke Laboratories as part of the HVTN Laboratory Center are utilizing state of the art technologies to comprehensively interrogate the humoral immune response to HIV vaccines to identify and characterize protective immune responses.